Stock Analiz

Alpha Teknova, Inc. TKNO

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2021 · data as of November 13, 2026

$8.21Market cap $516M
Open the interactive analysis →

Alpha Teknova, Inc. (TKNO) is a healthcare company listed in the US with a market value of about $516M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$16M, a net margin of -34.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -21%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Alpha Teknova

Alpha Teknova is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2021. Revenue went from $31M in 2020 to $41M in 2025, growth of about 5.3% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 90% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.2
P/B8.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.2%
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)7.3%
Revenue growth (5 yrs, per year)5.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-71.0%
ROIC (5-yr avg.)-21.2%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$46M$41M$38M$37M$41M$37M$31M
Net income-$16M-$17M-$27M-$37M-$47M-$10M$4M
Free cash flow-$6M-$10M-$14M-$27M-$56M-$29M-$3M
EPS (diluted)$-0.29$-0.32$-0.57$-1.16$-1.69$-0.61$0.16
Net margin-34.8%-42.6%-70.9%-100.3%-114.6%-26.6%11.4%
ROIC—-13.8%-24.0%-29.3%-33.6%-5.3%21.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $9.83, 20% above the current price; targets range from $8.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.23 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Alpha Teknova stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Alpha Teknova pay a dividend?

Not currently.

Is Alpha Teknova a good stock to buy?

We do not give buy or sell advice. Alpha Teknova scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.